ReachMD CME

CME credits: 0.50
Valid until: 30-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/acc-2024-voyager-pad-part-2/24407/

This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.

CME credits: 1.00
Valid until: 19-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-arterial-hypertension-screening-diagnosis-and-optimizing-management/24048/

Learn how to use guideline recommendations to establish a diagnosis of pulmonary arterial hypertension (PAH), develop evidence-based individualized treatment plans, and explore innovative therapies under investigation for PAH management. Hear from expert faculty on how to integrate the patient’s perspective when personalizing management plans for PAH.

=

CME credits: 1.00
Valid until: 25-10-2024
Claim your CME credit at https://reachmd.com/programs/cme/overcoming-barriers-to-timely-diagnosis-and-classification-of-interstitial-lung-disease-considerations-for-radiologists/24047/

Learn about making timely and accurate diagnoses of ILD, review radiologic patterns, and discuss the importance of multidisciplinary care in radiology.

=

CME credits: 1.00
Valid until: 12-11-2024
Claim your CME credit at https://reachmd.com/programs/cme/experts-on-the-ground-new-data-and-practical-clinical-integration-of-therapies-approved-for-igan/24046/

Expert Nephrologist Pietro Canetta, MD, MS, gives an overview of top abstracts from Kidney Week 2023 and new therapies for IgAN.

=

CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-therapeutic-selection-for-a-patient-with-newly-diagnosed-braf-v600e-mutated-metastatic-melanoma/24365/

This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.

CME credits: 1.50
Valid until: 26-07-2024
Claim your CME credit at https://reachmd.com/programs/cme/leading-the-charge-on-obesity-management-the-endocrinologists-role-in-empowering-community-providers-to-join-the-fight/18078/

Gain experts’ insights and tools for endocrinology specialists to use to support and empower community-based colleagues in successful and sustainable obesity management practices.

=

CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-consult-adjuvant-therapy-following-localized-treatment-for-stage-iii-melanoma/24381/

This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.

CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-dermatologists-surgeons-need-to-know-adjuvant-treatment-for-resectable-stage-iiiiv-melanoma/24380/

This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.

CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/unlocking-synergy-exploring-the-interaction-between-lag-3-and-other-immune-checkpoints/24363/

This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.

CME credits: 0.75
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-immunotherapy-related-adverse-events-during-adjuvant-treatment-for-resectable-melanoma/24382/

This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.